Verona Pharma

chronic obstructive pulmonary disease
#Approvals #Chronic obstructive pulmonary disease (COPD) #Drug approvals #FDA #Verona Pharma

Verona Pharma submits COPD drug ensifentrine for US FDA approval 

Verona Pharma has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).  Ensifentrine is a selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and non-steroidal… Read More

#News #Regulatory